Drug maker Lupin Monday said its US subsidiary Lupin Pharmaceuticals Inc has launched the generic version of Rabeprazole Sodium delayed-release tablet 20mg in the US market.
Lupin had earlier received final approval from the US regulator for the drug, indicated for the treatment of Gastroesophageal reflux disease (GERD).
Lupin's Rabeprazole Sodium delayed-release tablets, 20mg, are the generic equivalent of Eisai Inc.'s brand Aciphex, which clocked in $864 million in July 2012 - June 2013, as per IMS data.
Lupin has launched 11 products in the US market this year and received 15 approvals.
